Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis

被引:0
作者
Targownik, Laura [1 ]
Afif, Waqqas [2 ]
Singh, Sunny [3 ]
Siffledeen, Jesse [4 ]
Ma, Christopher [5 ,6 ]
McHugh, Kevin [7 ]
Charbonneau, Julie [7 ]
Rioux, Louis-Charles [8 ]
机构
[1] Univ Toronto, Mt Sinai Hosp, Dept Gastroenterol & Hepatol, 600 Univ Ave, Toronto, ON M5G 1X5, Canada
[2] McGill Univ, Montreal Gen Hosp, Dept Med, Montreal, PQ H3G 1A4, Canada
[3] Univ British Columbia, Kelowna Gen Hosp, Dept Med, Div Gastroenterol, Kelowna, BC, Canada
[4] Univ Alberta, Div Gastroenterol, Edmonton, AB, Canada
[5] Univ Calgary, Cumming Sch Med, Dept Med, Div Gastroenterol & Hepatol, Calgary, AB, Canada
[6] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Div Gastroenterol & Hepatol, Calgary, AB T2N 4N1, Canada
[7] AbbVie Corp, St Laurent, PQ, Canada
[8] Univ Montreal, Hop Maisonneuve Rosemont, Div Gastroenterol, Montreal, PQ, Canada
关键词
biologics; sequencing; therapeutics; MAINTENANCE THERAPY; CROHNS-DISEASE; ULCERATIVE-COLITIS; CLINICAL-PRACTICE; INDUCTION; USTEKINUMAB; ADALIMUMAB; MULTICENTER; VEDOLIZUMAB; MANAGEMENT;
D O I
10.1093/jcag/gwae040
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Inflammatory bowel disease (IBD) is made up of ulcerative colitis (UC) and Crohn's disease (CD). However, modern medicines for IBD are not always effective. For some patients, the medicine doesn't work, or it stops working after a while. Other patients have to stop taking their medicine because of side effects. Patients like these usually have to change the dose or switch to another medicine.The RECORDED study looked at Canadian patients who had to change their IBD medicine. The researchers were interested in finding out how long they received their first medicine before changing to a different one.The study looked at 330 patients with CD and 344 patients with UC across Canada. Patients with CD switched to a different medicine on average after 12 months. Patients with UC switched to a different medicine on average after 9 months. In most cases, the medicine was stopped because it didn't work or because it caused side effects. The dose of the first medicine was changed in 191 CD patients and 202 UC patients before it was stopped.The RECORDED study shows what treatment patterns look like for Canadians with IBD who had to change their medicine at least once.
引用
收藏
页码:21 / 30
页数:10
相关论文
共 29 条
[11]   Infliximab for medical induction of remission in Crohn's disease [J].
Gordon, Morris ;
Radford, Shellie J. ;
Eldragini, Mohsen Ebrahim Abdelhamid Ali ;
Darie, Ana-Maria ;
Sinopoulou, Vassiliki ;
Akobeng, Anthony K. ;
Moran, Gordon William .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (11)
[12]   Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience [J].
Hoque, Sami ;
Puenpatom, Amy ;
Boccaletti, Simona ;
Green, Chloe ;
Black, Christopher M. ;
Roberts, Jenna ;
Rajkovic, Ivana ;
Milligan, Gary .
BMJ OPEN GASTROENTEROLOGY, 2020, 7 (01)
[13]   Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease [J].
Huinink, Sebastiaan ten Bokkel ;
Biemans, Vince ;
Duijvestein, Marjolijn ;
Pierik, Marieke ;
Hoentjen, Frank ;
West, Rachel L. ;
van der Woude, Christien J. ;
de Vries, Annemarie C. .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 :E783-E788
[14]  
HUMIRA (Adalimumab) Injection, 2022, PRODUCT MONOGRAPH
[15]   ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse [J].
Jairath, Vipul ;
Yarur, Andres ;
Osterman, Mark T. ;
James, Alexandra ;
Balma, Diane ;
Mehrotra, Shailly ;
Yang, Lili ;
Yajnik, Vijay ;
Khan, Rana M. Qasim .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (05) :1077-+
[16]   Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study [J].
Ko, Yanna ;
Paramsothy, Sudarshan ;
Yau, Yunki ;
Leong, Rupert W. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (03) :292-301
[17]  
Panaccione R, 2019, CLIN GASTROENTEROL H, V17, P1680, DOI [10.1016/j.cgh.2019.02.043, 10.1093/jcag/gwz019]
[18]   Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? [J].
Papamichael, Konstantinos ;
Cheifetz, Adam S. .
CURRENT OPINION IN GASTROENTEROLOGY, 2019, 35 (04) :302-310
[19]   Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST [J].
Peyrin-Biroulet, Laurent ;
Vermeire, Severine ;
D'Haens, Geert ;
Panes, Julian ;
Dignass, Axel ;
Magro, Fernando ;
Nazar, Maciej ;
Le Bars, Manuela ;
Lahaye, Marjolein ;
Ni, Lioudmila ;
Bravata, Ivana ;
Lavie, Frederic ;
Daperno, Marco ;
Lukas, Milan ;
Armuzzi, Alessandro ;
Loewenberg, Mark ;
Gaya, Daniel R. ;
Danese, Silvio .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) :175-185
[20]   Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience [J].
Pouillon, Lieven ;
Baumann, Cedric ;
Rousseau, Helene ;
Choukour, Myriam ;
Andrianjafy, Charlotte ;
Danese, Silvio ;
Peyrin-Biroulet, Laurent .
INFLAMMATORY BOWEL DISEASES, 2019, 25 (05) :945-954